A selective inhibitor reveals PI3Kγ dependence of TH17 cell differentiation

Nature Chemical Biology

Volumn 8, Issue 6, 2012, Pages 576-582

  Bergamini, Giovanna ^a   Bell, Kathryn ^b   Shimamura, Satoko ^a   Werner, Thilo ^a   Cansfield, Andrew ^b   Müller, Katrin ^a   Perrin, Jessica ^a   Rau, Christina ^a   Ellard, Katie ^b   Hopf, Carsten ^a   Doce, Carola ^a   Leggate, Daniel ^b   Mangano, Raffaella ^b   Mathieson, Toby ^a   O'Mahony, Alison ^c   Plavec, Ivan ^c   Rharbaoui, Faiza ^a   Reinhard, Friedrich ^a   Savitski, Mikhail M ^a   Ramsden, Nigel ^b   Hirsch, Emilio ^d   Drewes, Gerard ^a   Rausch, Oliver ^b   Bantscheff, Marcus ^a   Neubauer, Gitte ^a   more..

^a GLAXOSMITHKLINE   (United Kingdom)

^b Cellzome Ltd   (United Kingdom)

^c BioSeek LlC   (United States)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CZC 19091; CZC 19945; CZC 24832; INTERLEUKIN 17; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BIOAVAILABILITY; DRUG DEVELOPMENT; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; IMMUNODETECTION; IMMUNOMODULATION; INFLAMMATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RAT; SINGLE DRUG DOSE; TH17 CELL;

EID: 84861329091     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.957     Document Type: Article

References (49)

1. Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M. & Bilanges, B. The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 11, 329-341 (2010).
2. Hawkins, P.T., Anderson, K.E., Davidson, K. & Stephens, L.R. Signalling through Class I PI3Ks in mammalian cells. Biochem. Soc. Trans. 34, 647-662 (2006). (Pubitemid 44796393)
3. Bohnacker, T. et al. PI3K+adaptor subunits define coupling to degranulation and cell motility by distinct PtdIns(3,4,5)P3 pools in mast cells. Sci. Signal. 2, ra27 (2009).
4. Ghigo, A., Damilano, F., Braccini, L. & Hirsch, E. PI3K inhibition in inflammation: toward tailored therapies for specific diseases. Bioessays 32, 185-196 (2010).
5. Foukas, L.C. et al. Critical role for the p110-phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441, 366-370 (2006). (Pubitemid 44050203)
6. Ji, H. et al. Inactivation of PI3K-and PI3K-distorts T-cell development and causes multiple organ inflammation. Blood 110, 2940-2947 (2007). (Pubitemid 350006947)
7. Ciraolo, E. et al. Phosphoinositide 3-kinase p110-activity: key role in metabolism and mammary gland cancer but not development. Sci. Signal. 1, ra3 (2008).
8. Maira, S.M. et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851-1863 (2008).
9. Brachmann, S.M. et al. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc. Natl. Acad. Sci. USA 106, 22299-22304 (2009).
10. Konstantinidou, G. et al. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res. 69, 7644-7652 (2009).
11. Toledo, L.I. et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat. Struct. Mol. Biol. 18, 721-727 (2011).
12. Bantscheff, M. et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035-1044 (2007). (Pubitemid 47517638)
13. Bantscheff, M. et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat. Biotechnol. 29, 255-265 (2011).
14. Kruse, U. et al. Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells. Leukemia 25, 89-100 (2011).
15. Knight, Z.A. et al. A pharmacological map of the PI3-K family defines a role for p110-in insulin signaling. Cell 125, 733-747 (2006).
16. Vlahos, C.J., Matter, W.F., Hui, K.Y. & Brown, R.F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1- benzopyran-4-one (LY294002). J. Biol. Chem. 269, 5241-5248 (1994).
17. Cansfield, A., Bergamini, G. & Neubauer, G. Selectivity profiling of PI3K interacting molecules against multiple targets. European patent EP2245181 (2011).
18. Jefferies, H.B. et al. A selective PIKfyve inhibitor blocks PtdIns(3,5)P(2) production and disrupts endomembrane transport and retroviral budding. EMBO Rep. 9, 164-170 (2008). (Pubitemid 351223454)
19. Sharma, K. et al. Proteomics strategy for quantitative protein interaction profiling in cell extracts. Nat. Methods 6, 741-744 (2009).
20. Berg, E.L. et al. Chemical target and pathway toxicity mechanisms defined in primary human cell systems. J. Pharmacol. Toxicol. Methods 61, 3-15 (2010).
21. Hirsch, E. et al. Central role for G protein-coupled phosphoinositide 3-kinase ? in inflammation. Science 287, 1049-1053 (2000).
22. Jones, G.E. et al. Requirement for PI 3-kinase-in macrophage migration to MCP-1 and CSF-1. Exp. Cell Res. 290, 120-131 (2003). (Pubitemid 37153256)
23. Savitski, M.M. et al. Targeted data acquisition for improved reproducibility and robustness of proteomic mass spectrometry assays. J. Am. Soc. Mass Spectrom. 21, 1668-1679 (2010).
24. Williams, O. et al. Discovery of dual inhibitors of the immune cell PI3Ks p110-and p110: a prototype for new anti-inflammatory drugs. Chem. Biol. 17, 123-134 (2010).
25. Mitsdoerffer, M. et al. Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc. Natl. Acad. Sci. USA 107, 14292-14297 (2010).
26. Zhou, L. et al. IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8, 967-974 (2007). (Pubitemid 47300011)
27. Patrucco, E. et al. PI3K-modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and-independent effects. Cell 118, 375-387 (2004). (Pubitemid 39061117)
28. Rommel, C., Camps, M. & Ji, H. PI3K-and PI3K+ : partners in crime in inflammation in rheumatoid arthritis and beyond? Nat. Rev. Immunol. 7, 191-201 (2007).
29. Rückle, T., Schwarz, M.K. & Rommel, C. PI3K-inhibition: towards an 'aspirin of the 21st century'? Nat. Rev. Drug Discov. 5, 903-918 (2006). (Pubitemid 44660604)
30. Martin, D. et al. PI3K-mediates Kaposi's sarcoma-associated herpesvirus vGPCR-induced sarcomagenesis. Cancer Cell 19, 805-813 (2011).
31. Schmid, M.C. et al. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3K+, a single convergent point promoting tumor inflammation and progression. Cancer Cell 19, 715-727 (2011).
32. Becattini, B. et al. PI3K-within a nonhematopoietic cell type negatively regulates diet-induced thermogenesis and promotes obesity and insulin resistance. Proc. Natl. Acad. Sci. USA 108, E854-E863 (2011).
33. Kobayashi, N. et al. Blockade of class IB phosphoinositide-3 kinase ameliorates obesity-induced inflammation and insulin resistance. Proc. Natl. Acad. Sci. USA 108, 5753-5758 (2011).
34. Fougerat, A. et al. Genetic and pharmacological targeting of phosphoinositide 3-kinase-reduces atherosclerosis and favors plaque stability by modulating inflammatory processes. Circulation 117, 1310-1317 (2008). (Pubitemid 351365672)
35. Fadden, P. et al. Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90. Chem. Biol. 17, 686-694 (2010).
36. Graves, P.R. et al. Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol. Pharmacol. 62, 1364-1372 (2002). (Pubitemid 35403831)
37. Camps, M. et al. Blockade of PI3K-suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 11, 936-943 (2005). (Pubitemid 41294438)
38. Bilancio, A. et al. Key role of the p110-isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110-function in B cells. Blood 107, 642-650 (2006). (Pubitemid 43076389)
39. Condliffe, A.M. et al. Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 106, 1432-1440 (2005). (Pubitemid 41129612)
40. Vecchione, C. et al. Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3K+. J. Exp. Med. 201, 1217-1228 (2005). (Pubitemid 40629066)
41. Haylock-Jacobs, S. et al. PI3K-drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting TH17 differentiation. J. Autoimmun. 36, 278-287 (2011).
42. Konrad, S. et al. Phosphoinositide 3-kinases and linkers of coordinate C5a receptor-Fc-receptor activation and immune complex-induced inflammation. J. Biol. Chem. 283, 33296-33303 (2008).
43. Lubberts, E. et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 50, 650-659 (2004). (Pubitemid 38198849)
44. Genovese, M.C. et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 62, 929-939 (2010).
45. Kageyama, Y., Kobayashi, H. & Kato, N. Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis. Mod. Rheumatol. 19, 657-662 (2009).
46. Savitski, M.M. et al. Delayed fragmentation and optimized isolation width settings for improvement of protein identification and accuracy of isobaric mass tag quantification on Orbitrap-type mass spectrometers. Anal. Chem. 83, 8959-8967 (2011).
47. Savitski, M.M., Scholten, A., Sweetman, G., Mathieson, T. & Bantscheff, M. Evaluation of data analysis strategies for improved mass spectrometry-based phosphoproteomics. Anal. Chem. 82, 9843-9849 (2010).
48. Kunkel, E.J. et al. An integrative biology approach for analysis of drug action in models of human vascular inflammation. FASEB J. 18, 1279-1281 (2004). (Pubitemid 39561576)
49. Kunkel, E.J. et al. Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models. Assay Drug Dev. Technol. 2, 431-441 (2004). (Pubitemid 39276284)